GlassScriptPhysician profile
John R Salyer
NPI 1952304966
$746.17
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $116.47 | 2019 | |
| Glaxosmithkline, LLC. | $77.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $73.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.57 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $45.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.34 | 2019 | |
| Cepheid | $33.18 | 2019 | |
| Eisai INC. | $30.69 | 2020 | |
| Pfizer INC. | $25.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.33 | 2019 | |
| Shire North American Group INC | $22.67 | 2019 | |
| Amgen INC. | $17.52 | 2019 | |
| Allergan, INC. | $13.40 | 2019 | |
| Lilly USA, LLC | $12.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Salyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.